Nasdaq

Capivasertib plus FASLODEX® (fulvestrant) significantly improved progression-free survival vs. FASLODEX in CAPItello-291 Phase III trial in advanced HR-positive breast cancer

Capivasertib, a potential first-in-class AKT inhibitor, combined with FASLODEX could become a new option for patients in this setting regardless of biomarker status WILMINGTON, Del.--(BUSINESS WIRE)-- ...
Business Wire

VeraMorph Awarded an SBIR Fast Track Grant by NCI Towards Commercialization of the First Effective Oral Fulvestrant Therapy for ER+ Metastatic Breast Cancer

NORWOOD, Mass.--(BUSINESS WIRE)--Veramorph LLC (VeraMorph), a science-driven startup developing a novel degradable gel as a solubility-enhancing oral drug delivery technology, has been awarded a Small ...
Business Wire

Dr. Reddy's Laboratories Announces the Launch of Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per Single-Dose Syringe in the U.S. Market

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today ...
ots

AstraZeneca Begins a New Global Study of FASLODEX® (Fulvestrant) 500 mg Injection in Patients With Hormone Receptor-Positive Advanced Breast Cancer

have not previously been treated with any hormonal therapy. In the FALCON study, eligible patients will be randomised 1:1 to receive either fulvestrant (500 mg/day intramuscular injection) on days 0, ...